Company buys majority position in Russian pharma manufacturing facility.

Actavis acquired a 51% controlling interest in ZiO Zdorovje, a Russian pharmaceutical manufacturer.
Out of a total cost of $60 million for the deal, $30 million will be targeted for investment in the ZiO Zdorovje manufacturing site with the goals of creating a platform for increased production and capacity as well as introducing new products.

The current owners of ZiO Zdorovje will retain a 49% stake in the business.

Previous articleNational Library of Medicine Awards $75M for Informatics Research Training
Next articleRockeby Initiates Strategic Investment with Anheal